TSVT News and Press, 2seventy bio Inc. From 09/08/22

Summary Shares have lost over 40% of their value since the spinoff in November. The pipeline has multiple shots on goal including in solid tumors and AML plus validating partnerships via Regeneron and BMY. A successful interim readout for its KARMA-3 study sped up the clinical...

This study will evaluate Abecma in patients with suboptimal response to transplant Data from KarMMa-3 and KarMMa-2 studies of Abecma will be presented at future medical meeting 2seventy bio, Inc. (Nasdaq: TSVT) today announced plans to initiate the KarMMa...

Abecma, a CAR-T myeloma therapy, is rapidly ramping revenue. 2seventy has $398 million in cash. Multiple advanced T-cell platforms could generate many more successful therapies. 2seventy bio ( TSVT ) was spun off from bluebird bio ( BLUE ) in November 2021. It st...

2seventy bio press release ( NASDAQ: TSVT ): Q2 GAAP EPS of -$2.02 misses by $0.09 . Revenue of $13.48M (+83.9% Y/Y) misses by $3.04M . Ended quarter with $399M cash, cash equivalents, and marketable securities; revising 2022 net cash spend to $245-265M; mainta...

Bristol Myers Squibb ( NYSE: BMY ) and its partner 2seventy bio ( TSVT ) announced on Wednesday that a Phase 3 trial for Abecma a CAR T cell therapy they jointly develop reached the main goal in certain adult patients with multiple myeloma. 2seventy bio ( TSVT ) adde...

ABECMA generated $ 72M U.S. commercial revenue in 2Q; continues to track toward upper end of $250-$300M revenue guidance for 2022 Results from prespecified interim analysis of KarMMa-3 trial shows ABECMA (idecabtagene vicleucel) significantly improves progression-free ...

Abecma is the first BCMA-directed CAR T cell therapy to demonstrate superiority versus standard regimens in relapsed and refractory multiple myeloma Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) today announced positive topline results fr...

2seventy bio, Inc . (Nasdaq: TSVT) announced today that members of the management team will participate in the following upcoming investor conferences: 2022 Wedbush PacGrow Healthcare Conference, “A View to a Kill(er Cell) – Part 1” panel on Wednesday, Aug...

For further details see: Arcellx named new buy at Canaccord Genuity on multiple myeloma candidate

InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article is excerpted from Tom Yeung’s Profit & Protection newsletter. To make sure you don’t miss any of Tom’s picks, subscribe to his mailing list here . June’s No. 1 Profit &...